Orbus Pharma Inc. (“Orbus”) (TSX:ORB) today announced that it has entered into a new strategic collaboration with Alfred E. Tiefenbacher (GmbH & Co.) of Hamburg, Germany (“AET”) to co-develop and supply famciclovir tablets for the European market.
Orbus Pharma Inc. (“Orbus”) (TSX:ORB) today announced that it has entered into a new strategic collaboration with Alfred E. Tiefenbacher (GmbH & Co.) of Hamburg, Germany (“AET”) to co-develop and supply famciclovir tablets for the European market.
